आइरिस या रेटिनल नव-रक्तवाहिनीकरण के साथ केंद्रीय रेटिनल शिरा अवरोध का उपचार

References

1. In patients with CRVO with retinal and/or iris neovascularization, dense peripheral PRP is indicated.
2. For individuals who develop iris neovascularization or retinal neovascularization following a CRVO, the best long-term treatment is often dense peripheral panretinal photocoagulation surgery (PRP).
3. Additionally, anti-VEGF agents that may or may not treat other targets can be used in an adjunctive manner when complete PRP is insufficient to control angiogenesis.
4. Often, initial treatment with an anti-VEGF agent is helpful for an immediate but not a sustained benefit, and it may also improve the ability to deliver a complete laser surgery treatment.
5. Anti-vascular endothelial growth factor agents are commonly used to treat the macular edema, reduce the severity of anterior segment neovascularization, and lower the risk of ocular angiogenesis.